Overview

* Viatris Q2 2025 revenue beats expectations despite 6% decline yr/yr

* Adjusted EPS for Q2 2025 beats analyst expectations, per LSEG data

* Company returned over $630 mln to shareholders, including $350 mln in buybacks

Outlook

* Viatris ( VTRS ) expects 2025 total revenues between $13.5 bln and $14.0 bln

* Company sees 2025 adjusted EPS between $2.16 and $2.30

* Viatris ( VTRS ) estimates 2025 free cash flow between $1.8 bln and $2.2 bln

* Company expects to be in top half of revenue and EPS guidance ranges

Result Drivers

* INDORE IMPACT - Negative financial impact from FDA warning letter and import alert on Indore facility affected revenue

* BRANDS PERFORMANCE - Strong sales in Greater China and Emerging Markets contributed positively to results

* GENERIC SALES - Expected decline due to Indore Impact and competition, offset by growth in specific products and regions

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $3.58 $3.47

Revenue bln bln (5

Analysts

)

Q2 Beat $0.62 $0.56 (5

Adjusted Analysts

EPS )

Q2 Net -$4.60

Income mln

Q2 Beat $1.08 $1.06

Adjusted bln bln (2

EBITDA Analysts

)

Q2 Gross 37.2%

Margin

Q2 56.6%

Adjusted

Gross

Margin

Q2 Free $166.80

Cash mln

Flow

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 6 "hold" and 2 "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy."

* Wall Street's median 12-month price target for Viatris Inc ( VTRS ) is $10.50, about 16.7% above its August 6 closing price of $8.75

* The stock recently traded at 4 times the next 12-month earnings vs. a P/E of 4 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)